The strong unit sales growth and physician adoption metrics suggest accelerating commercial traction for CyPath Lung. Monitor upcoming quarterly results (10-Q) for actual revenue and gross margin data. The Philips collaboration for veteran screening could expand addressable market. With a $4M market cap and no current revenue disclosure, the stock may be highly volatile on any future revenue or partnership announcements.
Price Chart
Executive Summary
bioAffinity Technologies released a Q2 2026 newsletter announcing CyPath Lung unit sales in April increased nearly 300% YoY and a 69% increase in ordering physician offices from Q1 2025 to Q1 2026, along with a collaboration with Philips to advance lung cancer screening for U.S. veterans. The filing is a routine corporate communication providing an operational update with no financial statements or material definitive agreements.
Key Facts
- CyPath Lung unit sales in April 2026 increased nearly 300% compared to April 2025.
- Number of physician offices and clinics ordering CyPath Lung increased 69% from Q1 2025 to Q1 2026.
- Company announced a collaboration with Philips to enhance lung cancer screening for U.S. veterans.
- Pipeline includes companion diagnostics for asthma/COPD (pilot study with Brooke Army Medical Center) and topical therapeutics for skin cancer (preclinical research).
- Market cap is approximately $4M with no analyst bullish ratings.
- Mexico patent allowance received for CyPath Lung technology.
Financial Impact
CyPath Lung unit sales nearly 300% YoY growth in April 2026; no revenue or margin figures provided.
Risk Factors
- Very small market cap ($4M) with limited liquidity and 0% analyst bullish rating.
- No financial statements or revenue data provided in the newsletter; forward-looking statements only.
- Relies on laboratory developed test regulatory environment which is subject to change.
- Early-stage pipeline (asthma/COPD diagnostics, skin cancer therapeutics) has no near-term revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-031327 |
| Exhibit: ex99-1.htm | 0001493152-26-031327 |
| Document: 0001493152-26-031327-index-headers.html | 0001493152-26-031327 |
| Document: 0001493152-26-031327-index.html | 0001493152-26-031327 |
| Document: 0001493152-26-031327.txt | 0001493152-26-031327 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers